Literature DB >> 14602724

IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi.

Irlando Andrade Ferreira1, Kurt L Eybrechts, Astrid I M Mocking, Christine Kroner, Jan-Willem N Akkerman.   

Abstract

Platelet agonists initiate aggregation and secretion by activating receptors coupled to the G-protein G(q), thereby raising cytosolic Ca(2+), [Ca(2+)](i). The rise in [Ca(2+)](i) is facilitated via inhibition of cAMP formation by the inhibitory G-protein of adenylyl cyclase, G(i). Since insulin attenuates platelet activation, we investigated whether insulin interferes with cAMP regulation. Here we report that insulin (0.5-200 nmol/liter) interferes with agonist-induced increases in [Ca(2+)](i) (ADP, thrombin), cAMP suppression (thrombin), and aggregation (ADP). The effects of insulin are as follows: (i) independent of the P2Y(12) receptor, which mediates ADP-induced cAMP lowering; (ii) not observed during G(s)-mediated cAMP formation; (iii) unaffected by treatments that affect phosphodiesterases (3-isobutyl-1-methylxanthine); and (iv) not changed by interfering with NO-mediated regulation of cAMP degradation (N(G)-monomethyl-l-arginine). Hence, insulin might interfere with G(i). Indeed, insulin induces the following: (i) tyrosine phosphorylation of the insulin receptor, the insulin receptor substrate-1 (IRS-1) and G(i)alpha(2); (ii) co-precipitation of IRS-1 with G(i)alpha(2) but not with other G alpha subunits. Despite persistent receptor activation, the association of IRS-1 with G(i)alpha(2) is transient, being optimal at 5 min and 1 nmol/liter insulin, which is sufficient to suppress Ca(2+) signaling by ADP, and at 10 min and 100 nmol/liter insulin, which is required to suppress Ca(2+) signaling by thrombin. Epinephrine, a known platelet sensitizer and antagonist of insulin, abolishes the effect of insulin on [Ca(2+)](i), tyrosine phosphorylation of G(i)alpha(2), and aggregation by interfering with the phosphorylation of the insulin receptor beta subunit. We conclude that insulin attenuates platelet functions by interfering with cAMP suppression through IRS-1 and G(i).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14602724     DOI: 10.1074/jbc.M305474200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.

Authors:  Dharam J Kumbhani; Steven P Marso; Carlos A Alvarez; Darren K McGuire
Journal:  Curr Cardiovasc Risk Rep       Date:  2015-01

2.  Impact of impaired glucose tolerance on clopidogrel response in patients with coronary artery disease.

Authors:  Masafumi Ueno; Kosuke Fujita; Hiroyuki Yamamoto; Tomoyuki Ikeda; Tatsuya Suga; Kenji Yamaji; Shinichiro Ikuta; Kazuhiro Kobuke; Yoshitaka Iwanaga; Dominick J Angiolillo; Shunichi Miyazaki
Journal:  J Thromb Thrombolysis       Date:  2015-08       Impact factor: 2.300

Review 3.  Diabetes and antiplatelet therapy: from bench to bedside.

Authors:  Jose R Rivas Rios; Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

4.  Alterations in insulin-signaling and coagulation pathways in platelets during hyperglycemia-hyperinsulinemia in healthy non-diabetic subject.

Authors:  A Koneti Rao; Robert J Freishtat; Gauthami Jalagadugula; Anamika Singh; Guangfen Mao; Andrew Wiles; Peter Cheung; Guenther Boden
Journal:  Thromb Res       Date:  2014-07-06       Impact factor: 3.944

Review 5.  Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus.

Authors:  S Farhan; I Tentzeris; M K Freynhofer; B Vogel; K Huber
Journal:  Herz       Date:  2012-05       Impact factor: 1.443

6.  Factors contributing to increased platelet reactivity in people with diabetes.

Authors:  David J Schneider
Journal:  Diabetes Care       Date:  2009-04       Impact factor: 17.152

7.  Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin.

Authors:  Anja J Gerrits; Cornelis A Koekman; Timon W van Haeften; Jan Willem N Akkerman
Journal:  Diabetes       Date:  2010-03-03       Impact factor: 9.461

Review 8.  Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions.

Authors:  Dominick J Angiolillo
Journal:  Diabetes Care       Date:  2009-04       Impact factor: 17.152

Review 9.  The Y's that bind: negative regulators of Src family kinase activity in platelets.

Authors:  D K Newman
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

10.  Insulin, insulin resistance, and platelet signaling in diabetes.

Authors:  Voahanginirina Randriamboavonjy; Ingrid Fleming
Journal:  Diabetes Care       Date:  2009-04       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.